The Cell Cycle as Therapeutic Target

References

• Wong G G, Witek J, Temple P A. Human GM-CSF molecular cloning of the complementary DNA and purification of the natural and recombinant protein. Science 1985; 228: 810
   PubMed Web of Science ®Google Scholar
• Souza L M, Boone T C, Gabrilove J L. Recombinant human granulocyte colony-stimulating factor: Effect on normal and leukemic myeloid cells. Science 1986; 232: 61
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Broxmeyer HE., Hittelman W N. Abrogating chemotherapy-induced myelosuppression by recombinant granu-locyte-macrophage colony-stimulating factor in patients with sarcoma: Protection at the progenitor cell level. J Clin Oncol 1992; 10: 1266
   PubMed Web of Science ®Google Scholar
• Broxmeyer H E, Benninger L, Patel S R. Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp Hematol 1994; 22: 100
   PubMed Web of Science ®Google Scholar
• Aglietta M, Piacibello W, Sanavio F. Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. J Clin Invest 1989; 83: 551
   PubMed Web of Science ®Google Scholar
• Gabrilove J L, Jakubowski A, Scher H. Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414
   PubMed Web of Science ®Google Scholar
• Schuchter L M, Luginbuhl W E, Meropol N J. The current status of toxicity protectants in cancer therapy. Semin Oncol 1992; 19: 742
   PubMed Web of Science ®Google Scholar
• Aglietta M, Mozeglio C, Pasquino P. Short-term administration of granulocyte-macrophage colony-stimulating factor decreases hematopoietic toxicity of cytostatic drugs. Cancer 1993; 72: 2970
   PubMed Web of Science ®Google Scholar
• Broxmeyer H E, Cooper S, Williams D E. Effects of purified recombinant human granulocyte-macrophage colony stimulating factor on growth characteristics of bone marrow hematopoietic progenitoriprecursor cells in patients on a phase 1 clinical trial. Exp Hematol 1988; 16: 594
   PubMed Web of Science ®Google Scholar
• Broxmeyer H E, Cooper S, Vadhan-Raj S. Cell cycle status of erythroid (BFU-E) progenitor cells from bone marrows of patients on a clinical trial with purified recombinant human granulocyte-macrophage colony stimulating factor. Exp Hematol 1989; 17: 455
   PubMed Web of Science ®Google Scholar
• Janik J, Miller L, Smith J, II. Prechemotherapy granulocytemacrophage colony-stimulating factor (GM-CSF) prevents topotecan-induced neutropenia. Proc Am Soc Clin Oncol 1993; 12: 1507, (abstract)
   Google Scholar
• Nemunaitis J, Rabinowe S N, Singer J W. Recombinant granulocyte macrophage colony-stimulating factor after autolo-gous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 164: 1773
   Google Scholar
• Griffin J, Young D. D., Herrmann D. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 1986; 67: 1448
   PubMed Web of Science ®Google Scholar
• Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990; 4: 826
   PubMed Web of Science ®Google Scholar
• Cannistra S A, Groshek P, Griffin I D. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989; 3: 328
   PubMed Web of Science ®Google Scholar
• Teichrnann J V, Ludwig W-D, Thiel E. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells. Int J Hematol 1992; 55: 255
   PubMed Web of Science ®Google Scholar
• Vellenga E, Ostapovicz D, O'Rouke B. Effects of recombinant IL-3, GM-CSF, and G-CSF on proliferation of leukemic donogenic cells in short-term and long-term cultures. Leukemia 1987; 1: 584
   PubMed Web of Science ®Google Scholar
• Ohno R, Tomonaga M, Kobayashi T. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990; 323: 871
   PubMed Web of Science ®Google Scholar
• Biichner T, Hiddemann W, Koenigsman M. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991; 78: 1190
   PubMed Web of Science ®Google Scholar
• Rowe J M, Anderson J, Mazza J J. Phase III randomized placebo-controlled study of granulocyte-macrophage colony stimulating factor (GM-CSF) in adult patients (55–70 years) with acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Group (ECOG). Blood 1993; 82: 329a, (Suppl 1)
   Web of Science ®Google Scholar
• Clarkson B, Strife A, Fried J. Studies of cellular proliferation in human leukemia. IV. Behavior of leukemic cells in 3 adults with acute leukemia given continuous infusion of 3H-thymidine for 8 to 10 days. Cancer 1970; 26: 1
   PubMed Web of Science ®Google Scholar
• Raza A, Maheshwari N, Mandava Z. Cell cycle and drug sensitivity studies of leukemic cells that appear relevant in determining response to chemotherapy in acute nonlymphocytic leukemia. Semin Oncol 1987; 14: 217, Suppl
   PubMed Web of Science ®Google Scholar
• Bettelheim P, Valent P, Andreeff M. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991; 77: 700
   PubMed Web of Science ®Google Scholar
• Estey E, Thail P F, Kantarjian H. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high dose ara-C + daunorubicin: Comparison to patient treated without GM-CSF. Blood 1992; 79: 2246
   PubMed Web of Science ®Google Scholar
• Biichner T, Hiddemann W, Rottmann R. Multiple course chemotherapy with or without GM-CSF priming long term administration for newly diagnosed AML. Proc Am Soc Clin Oncol 1993; 12: 301, (abstract)
   Google Scholar
• Ohno R, Naoe T, Kanamaru A. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994; 83: 2086
   PubMed Web of Science ®Google Scholar
• Bolwell B J. The use of G-CSF and GM-CSF in bone marrow transplantation. Cleveland Clin J Med 1993; 60: 291
   PubMed Web of Science ®Google Scholar
• Juttner C A, To L B, Haylock D N. Autologous blood stem cell transplantation. Transplant Proc 1989; 21: 2929
   PubMed Web of Science ®Google Scholar
• Kessinger A, Vose J M, Bierman P J. High dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: An alternative to bone marrow purging. Exp Hematol 1991; 19: 1013
   PubMed Web of Science ®Google Scholar
• MaCarthy D M, Goldman J M. Transfusion of circulating stem cells. Crit Rev Clin Lab Sci 1984; 20: 1
   PubMed Web of Science ®Google Scholar
• Richman C, Weiner R, Yankee R. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031
   PubMed Web of Science ®Google Scholar
• To L B, Shepperd K M, Haylock D N. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from peripheral blood. Exp Hematol 1990; 18: 442
   PubMed Web of Science ®Google Scholar
• Kotasek D, Shepherd W, Sage R E. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant; 1992; 9: 11
   PubMed Web of Science ®Google Scholar
• Socinski M A, Cannistra S A, Eiias A. Granulocyte-macrophage colony-stimulating factor expands the circulating haemo-poietic progenitor cell compartment in man. Lancet 1988; 1(8596)1194
   PubMed Web of Science ®Google Scholar
• Haas R, Hohaus S, Egerer G. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest. Bone Marrow Transplant 1992; 9: 459
   PubMed Web of Science ®Google Scholar
• Sheridan W P, Begley C G, Juttner C A. Effect of peripheral-blood progenitor cells mobilised by filgrastin (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640
   PubMed Web of Science ®Google Scholar
• Gianni A M, Bregni M, Stem A C. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2(8663)580
   PubMed Web of Science ®Google Scholar